NCT00430313|WithdrawnDMC
Study Stopped
No participants enrolled
Loading search results
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · NCI
REGISTRY · NCI CTRP
interventional
0
0 countries
N/A
Study Start
January 4, 2007
Actual (reported)Primary Completion
August 10, 2022
Actual (reported)Study Completion
August 10, 2022
Actual (reported)Objectives: This protocol is part of a larger grant funded by the NCI to create an international research center to study Traditional Chinese Medicine (TCM). All of the patients enrolled in this study will be treated at the Cancer Hospital, Fudan University, investigator's sister institution in Shanghai, China. No patients will be seen at MDACC. This protocol will be overseen by the Fudan University Institutional Review Board (IRB00002408) which has Federal Wide Assurance through the U.S. Department of Health \& Human Services (Approved: April 25, 2002). The research nurses have received training at MDACC and will receive regular oversight by MDACC personnel. The purpose of this randomized, placebo controlled study is to determine the effects of K1 acustimulation at controlling chemotherapy induced nausea and vomiting (CINV).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 10, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 4, 2007
Actual (reported)January 30, 2007
Actual (reported)February 1, 2007
Actual (reported)August 10, 2022
Actual (reported)August 10, 2022
Actual (reported)Level of Patient Nausea + Vomiting
Vomiting and nausea will be classified according to the WHO criteria. The four levels of nausea are defined as: 0=no nausea, 1=slight nausea, 2=obvious nausea affecting normal life, and 3-4=continual and serious nausea. The four levels of vomiting are defined as: 0=no vomiting, 1=vomiting 1-2 times/day, 2=vomiting 2-4 times/day, and 3-4=vomiting 5 times/day.
2 Years
Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
Electro-stimulation at a inactive site on the bottom of the foot (a "placebo" site).
Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
Electro-stimulation at a inactive site on the bottom of the foot (a "placebo" site).
Lorenzo Cohen, PHD
M.D. Anderson Cancer Center
0 participants (actual enrollment reported by the registry).
First Submitted
January 30, 2007
First Posted
February 1, 2007
Study Start
January 4, 2007
Actual (reported)Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
August 10, 2022
Actual (reported)Study Completion
August 10, 2022
Actual (reported)Last Updated
March 29, 2023
Record last verified: 2023-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: